Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis

Table 2 Characteristics of studies used to perform the meta-analysis

Ref.	Publication	Fingolimod group	Types of stroke	Age (mean ± SD)	Sex (male %)	Dose of fingolimod	Conclusion
Fu et al[15]	2014	11	AIS	62.3 ± 8.0	73	0.5 mg/d orally, 3 consecutive days after hospitalization	It could safely limit secondary tissue injury, decrease microvascular permeability, attenuate neurological deficits, and promote recovery.
Fu et al[16]	2014	11	ICH	60.7 ± 12.3	36	0.5 mg/d orally, 3 consecutive days after hospitalization	It could safely reduce PHE, attenuate neurologic deficits, and promote recovery.
Zhu et al[17]	2015	22	AIS	60.0 ± 2.5	59	0.5 mg/d orally, 3 consecutive days after hospitalization	In this pilot study, combination therapy of fingolimod and alteplase was well tolerated, which attenuated reperfusion injury and improved clinical outcomes in AIS patients.
Tian et al[18]	2018	23	AIS	67 ± 6.7	39	0.5 mg/d orally, 3 consecutive days after hospitalization	Fingolimod may enhance the efficacy of alteplase administration in the 4.5- to 6-h time window in patients with a proximal cerebral arterial occlusion and salvageable penumbral tissue by promoting both anterograde reperfusion and retrograde collateral flow.

SD: Standard deviation.